The change of BMD in postmenopausal osteoporosis women receiving an injection of rPTH 1-34 for 6 months and then no injection for 18 months

Objective: To investigate the change of bone mineral density (BMD) in postmenopausal osteoporosis Chinese women who received an injection of rPTH1-34 for 6 months, and then no injection for 18 months. Methods: Thirty postmenopausal osteoporosis Chinese women who met the including criteria without excluding the condition were randomly divided into 2 groups, trial group and control group. rPTH1- 34 20 μg and 600 mg elementary calcium were given to the trial group daily. The control group received Alfacalcidol 0.5 μg and elementary calcium 600 mg daily. The treatment continued for 6 months and was followed by stopping the anti-osteoporosis medicine for 18 months. BMD was measured before taking the medicine (baseline value) and after stopping for 18 months. The site included vertebrae L2-4, femoral neck and whole hip. In the two groups, the BMD ratio was higher than the baseline value after stopping treatment. Results: There were 4 subjects in the control group and 11 subjects in the trial group who completed the trial. In the control group, all 4 of the subject's BMD were lower than baseline after stopping the treatment for 18 months in all sites. There were 81.82% (9 cases) in the vertebral L2-4, 54.55% (6 cases) in the femur and 63.64% (7 cases) in the whole hip's BMD that were higher than baseline, p<0.05 in vertebral and whole hip contrast to control group, and p<0.057 in femoral neck. Conclusion: When stopping treatment for 18 months after injecting rPTH1-34 for six, there was a higher ratio of those whose BMD could be preserved. It showed that rPTH1-34 is an effective medicine in the treatment of Chinese women with postmenopausal osteoporosis.